293 related articles for article (PubMed ID: 27181332)
1. BCR-ABL-specific CD4
Ueda N; Zhang R; Tatsumi M; Liu TY; Kitayama S; Yasui Y; Sugai S; Iwama T; Senju S; Okada S; Nakatsura T; Kuzushima K; Kiyoi H; Naoe T; Kaneko S; Uemura Y
Cell Mol Immunol; 2018 Jan; 15(1):15-26. PubMed ID: 27181332
[TBL] [Abstract][Full Text] [Related]
2. Identification of new MHC-restriction elements for presentation of the p210(BCR-ABL) fusion region to human cytotoxic T lymphocytes.
Sun JY; Senitzer D; Forman SJ; Chatterjee S; Wong KK
Cancer Immunol Immunother; 2003 Dec; 52(12):761-70. PubMed ID: 14564482
[TBL] [Abstract][Full Text] [Related]
3. CD4(+) cytotoxic T-cell clones specific for bcr-abl b3a2 fusion peptide augment colony formation by chronic myelogenous leukemia cells in a b3a2-specific and HLA-DR-restricted manner.
Yasukawa M; Ohminami H; Kaneko S; Yakushijin Y; Nishimura Y; Inokuchi K; Miyakuni T; Nakao S; Kishi K; Kubonishi I; Dan K; Fujita S
Blood; 1998 Nov; 92(9):3355-61. PubMed ID: 9787173
[TBL] [Abstract][Full Text] [Related]
4. Generation of TCR-Expressing Innate Lymphoid-like Helper Cells that Induce Cytotoxic T Cell-Mediated Anti-leukemic Cell Response.
Ueda N; Uemura Y; Zhang R; Kitayama S; Iriguchi S; Kawai Y; Yasui Y; Tatsumi M; Ueda T; Liu TY; Mizoro Y; Okada C; Watanabe A; Nakanishi M; Senju S; Nishimura Y; Kuzushima K; Kiyoi H; Naoe T; Kaneko S
Stem Cell Reports; 2018 Jun; 10(6):1935-1946. PubMed ID: 29805109
[TBL] [Abstract][Full Text] [Related]
5. HLA class II-restricted antigen presentation of endogenous bcr-abl fusion protein by chronic myelogenous leukemia-derived dendritic cells to CD4(+) T lymphocytes.
Yasukawa M; Ohminami H; Kojima K; Hato T; Hasegawa A; Takahashi T; Hirai H; Fujita S
Blood; 2001 Sep; 98(5):1498-505. PubMed ID: 11520800
[TBL] [Abstract][Full Text] [Related]
6. Generation of bcr-abl specific cytotoxic T-lymphocytes by using dendritic cells pulsed with bcr-abl (b3a2) peptide: its applicability for donor leukocyte transfusions in marrow grafted CML patients.
Osman Y; Takahashi M; Zheng Z; Koike T; Toba K; Liu A; Furukawa T; Aoki S; Aizawa Y
Leukemia; 1999 Feb; 13(2):166-74. PubMed ID: 10025889
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of a p210(BCR-ABL) fusion domain candidate DNA vaccine targeted to dendritic cells by a recombinant adeno-associated virus vector in vitro.
Sun JY; Krouse RS; Forman SJ; Senitzer D; Sniecinski I; Chatterjee S; Wong KK
Cancer Res; 2002 Jun; 62(11):3175-83. PubMed ID: 12036931
[TBL] [Abstract][Full Text] [Related]
8. HLA-DR1-restricted bcr-abl (b3a2)-specific CD4+ T lymphocytes respond to dendritic cells pulsed with b3a2 peptide and antigen-presenting cells exposed to b3a2 containing cell lysates.
Mannering SI; McKenzie JL; Fearnley DB; Hart DN
Blood; 1997 Jul; 90(1):290-7. PubMed ID: 9207464
[TBL] [Abstract][Full Text] [Related]
9. b3a2 BCR-ABL fusion peptides as targets for cytotoxic T cells in chronic myeloid leukaemia.
Norbury LC; Clark RE; Christmas SE
Br J Haematol; 2000 Jun; 109(3):616-21. PubMed ID: 10886212
[TBL] [Abstract][Full Text] [Related]
10. Peptides derived from the whole sequence of BCR-ABL bind to several class I molecules allowing specific induction of human cytotoxic T lymphocytes.
Buzyn A; Ostankovitch M; Zerbib A; Kemula M; Connan F; Varet B; Guillet JG; Choppin J
Eur J Immunol; 1997 Aug; 27(8):2066-72. PubMed ID: 9295046
[TBL] [Abstract][Full Text] [Related]
11. A CD4+ T cell clone selected from a CML patient after donor lymphocyte infusion recognizes BCR-ABL breakpoint peptides but not tumor cells.
Zorn E; Orsini E; Wu CJ; Stein B; Chillemi A; Canning C; Alyea EP; Soiffer RJ; Ritz J
Transplantation; 2001 Apr; 71(8):1131-7. PubMed ID: 11374415
[TBL] [Abstract][Full Text] [Related]
12. Leukemia-associated fusion proteins, dek-can and bcr-abl, represent immunogenic HLA-DR-restricted epitopes recognized by fusion peptide-specific CD4+ T lymphocytes.
Makita M; Azuma T; Hamaguchi H; Niiya H; Kojima K; Fujita S; Tanimoto M; Harada M; Yasukawa M
Leukemia; 2002 Dec; 16(12):2400-7. PubMed ID: 12454745
[TBL] [Abstract][Full Text] [Related]
13. Specific human cellular immunity to bcr-abl oncogene-derived peptides.
Bocchia M; Korontsvit T; Xu Q; Mackinnon S; Yang SY; Sette A; Scheinberg DA
Blood; 1996 May; 87(9):3587-92. PubMed ID: 8611681
[TBL] [Abstract][Full Text] [Related]
14. Dendritic-cell-peptide immunization provides immunoprotection against bcr-abl-positive leukemia in mice.
He L; Feng H; Raymond A; Kreeger M; Zeng Y; Graner M; Whitesell L; Katsanis E
Cancer Immunol Immunother; 2001 Mar; 50(1):31-40. PubMed ID: 11315508
[TBL] [Abstract][Full Text] [Related]
15. Dendritic cells stimulate the expansion of bcr-abl specific CD8+ T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia.
Nieda M; Nicol A; Kikuchi A; Kashiwase K; Taylor K; Suzuki K; Tadokoro K; Juji T
Blood; 1998 Feb; 91(3):977-83. PubMed ID: 9446659
[TBL] [Abstract][Full Text] [Related]
16. Induction of BCR-ABL-specific immunity following vaccination with chaperone-rich cell lysates derived from BCR-ABL+ tumor cells.
Zeng Y; Graner MW; Thompson S; Marron M; Katsanis E
Blood; 2005 Mar; 105(5):2016-22. PubMed ID: 15374884
[TBL] [Abstract][Full Text] [Related]
17. CTLs specific for bcr-abl joining region segment peptides fail to lyse leukemia cells expressing p210 bcr-abl protein.
Chen W; Qin H; Reese VA; Cheever MA
J Immunother; 1998 Jul; 21(4):257-68. PubMed ID: 9672847
[TBL] [Abstract][Full Text] [Related]
18. [Construction of genetically modified dendritic cell vaccine expressing bcr/abl fusion gene and inducing specific cytotoxic T lymphocytes to kill K562 cells in vitro].
Wang WW; Huang RW; Hu Y; Li XD; Wang DN; He Y; Liu JJ
Ai Zheng; 2009 Jun; 28(6):602-6. PubMed ID: 19635197
[TBL] [Abstract][Full Text] [Related]
19. The generation of both T killer and Th cell clones specific for the tumor-associated antigen HER2 using retrovirally transduced dendritic cells.
zum Büschenfelde CM; Metzger J; Hermann C; Nicklisch N; Peschel C; Bernhard H
J Immunol; 2001 Aug; 167(3):1712-9. PubMed ID: 11466395
[TBL] [Abstract][Full Text] [Related]
20. Generation of autologous cytotoxic and helper T-cell responses against the B-cell leukemia-associated antigen HB-1: relevance for precursor B-ALL-specific immunotherapy.
de Rijke B; Fredrix H; Zoetbrood A; Scherpen F; Witteveen H; de Witte T; van de Wiel-Van Kemenade E; Dolstra H
Blood; 2003 Oct; 102(8):2885-91. PubMed ID: 12842998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
